Table 1.

Characteristics of the eight RCTs (L: lapatinib; T: trastuzumab)

Author	Phase	Groups	No. of patients per group	Neoadjuvant anti‐HER2 therapy	Duration of anti‐HER2 therapy
Bonnefoi H 17	II	L	22	1000mg daily	12weeks
		T	53	4mg/kg → 2mg/kg weekly	12weeks
		L+T	50	L:1000mg daily + T:2mg/kg weekly	12weeks
Baselga J 18	III	L	154	1500mg daily	18weeks
		T	149	4mg/kg → 2mg/kg weekly	18weeks
		L+T	152	L:1000mg daily + T:2mg/kg weekly	18weeks
Untch M 15	III	L	308	1250mg daily	24weeks
		T	307	8mg/kg → 6mg/kg every 3 weeks	24weeks
GuarneriV 3	II	L	38	1500mg daily	26weeks
		T	36	4mg/kg → 2mg/kg weekly	26weeks
		L+T	45	L:1000mg daily + T:2mg/kg weekly	26weeks
Robidoux A 6	III	L	171	1250mg daily	16weeks
		T	177	4mg/kg → 2mg/kg weekly	16weeks
		L+T	171	L:750mg daily + T:2mg/kg weekly	16weeks
Holmes FA 19	II	L	26	1250mg daily	26weeks
		T	29	4mg/kg → 2mg/kg weekly	26weeks
		L+T	23	L:750mg daily + T:2mg/kg weekly	26weeks
Carey L 16	III	L	64	1500mg daily	16weeks
		T	118	4mg/kg → 2mg/kg weekly	16weeks
		L+T	117	L:1000mg daily + T:2mg/kg weekly	16weeks
Alba E 20	II	L	52	1250mg daily	12weeks
		T	50	8mg/kg → 6mg/kg every 3 weeks	12weeks